Kidney Cancer Research

Two new studies suggest that a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.

The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies.

Results from a recent clinical trial show that post-surgical therapy with two anti-angiogenesis drugs does not improve progression-free survival for patients with kidney cancer and may cause serious side effects.

Researchers with The Cancer Genome Atlas (TCGA) report new findings on papillary renal cell carcinoma and prostate cancer.

Researchers in The Cancer Genome Atlas (TCGA) Network have uncovered a number of new findings about the biology and development of a rare form of kidney cancer. They found that the disease – chromophobe renal cell carcinoma – stems in part from alterations in genes in the mitochondria, the cell’s energy supplier.

Investigators in The Cancer Genome Atlas Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma.